Magazine Article | December 3, 2018

The Future Of Biopharma Hinges On The Ability To Manufacture

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

The biopharmaceutical industry is often credited as being one of the most innovative of all sectors. And while scientists in R&D are charged with finding new treatments and perhaps even cures for a wide variety of diseases with unmet medical needs, it is the engineers and their efforts in manufacturing that often make the difference in biopharma being able to deliver to patients. But the manufacturing process is becoming more challenging as we continue to move toward personalized medicines. For example, in 2017 Novartis received the first-ever FDA approval for a CAR-T cell therapy treatment — Kymriah (pronounced kim-rye-ah) for the treatment of patients up to age 25 with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. Yet less than one year later, the company announced having some variability in the manufacture of the product.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: